New Zealand markets close in 1 hour 9 minutes

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.3500-0.0800 (-2.33%)
At close: 4:00PM EDT
3.3000 -0.05 (-1.49%)
After hours: 06:37PM EDT

Aridis Pharmaceuticals, Inc.

983 University Avenue
Building B
Los Gatos, CA 95032
United States
408 385 1742
http://www.aridispharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees33

Key executives

NameTitlePayExercisedYear born
Dr. Vu L. TruongFounder, CEO & Director566.12kN/A1964
Dr. Hasan Jafri M.D.Chief Medical Officer412.88kN/AN/A
Dr. Eric J. PatzerExec. ChairmanN/AN/A1949
Mr. Fred KurlandInterim Principal Financial Officer & Principal Accounting OfficerN/AN/A1951
Mr. Jeffrey J. Fessler Esq., J.D.Acting Gen. CounselN/AN/A1963
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Corporate governance

Aridis Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.